key: cord-0844591-a6wjftv0
authors: Boroumand-Noughabi, Samaneh; Rahmati, Atefe; Morovatdar, Negar; Keramati, Mohammadreza
title: Diminution significative des taux de transfusion pendant la pandémie de COVID-19 dans le nord-est de l’Iran
date: 2021-12-29
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2021.12.004
sha: 539371b75c39e3e09ebceb0e5e8e33847e53eb08
doc_id: 844591
cord_uid: a6wjftv0

nan

The worldwide pandemic of the coronavirus disease 2019 (COVID-19) significantly influenced healthcare systems and disrupted daily lives. According to WHO's official report, among Asian countries with the coronavirus, Iran has the highest number of coronavirus deaths, followed by India [1] . The Iranian Blood Transfusion Organization (IBTO) experienced a significant reduction in blood donations and a subsequent shortage in blood stores which made hospitals decide to postpone elective surgeries [2] .

The study of the transfusion practices in this particular condition can affect the policies and planning with respect to transfusion management during other similar public health emergencies in the future. In this respect, so far, some studies have been conducted on the pattern of blood product consumption during the COVID-19 pandemic in different regions of the world. Studies conducted in Washington, Chicago, Maryland, Spain, China, and Singapore reported a decrease in blood product transfusion, ranged between 17.7% to 66.5% [3] [4] [5] [6] [7] . Similarly, a survey that assessed the transfusion demand in the Eastern Mediterranean Region (EMR) reported that most centers experienced a reduction of 10% to 50% and those who did not have active hematologyoncology departments [8] . The largest decrease among transfused blood components was seen in red blood cells (RBCs) with a 47.3% decrease. In the next place is cryoprecipitate (cryo) with 34.1%, followed by platelets (PLTs) with 18.9%. The lowest reduction was observed in fresh frozen plasma (FFP) units with 18.4%.

Comparing the transfusion rate for study timeframes, the total transfusion rates, as well as the transfusion rate of each blood component in COVID-19 patients, were significantly lower compared to non-COVID patients, except for FFP. The transfusion rate of FFP was also lower in COVID-19 patients but did not reach a statistical significance level (Table 1, Figure 1 ).

There is an intriguing point about the use of platelet and plasma products in different studies. The reduction in platelet consumption varies from 38.7% to 12.1%, while some studies have reported an increase of 10% [4] [5] [6] [7] [8] [9] . There could be several explanations for these differences. In our center, due to the active hematology-oncology department, our PLTs demand remained stable.

Furthermore, FFP and PLTs are frequently requested for the management of COVID-19associated coagulopathy and thrombocytopenia that are commonly presented in critically ill patients. care unit hospitalization. Patients with severe COVID-19 are supported with extracorporeal membrane oxygenation (ECMO), and performing such a procedure on patients is known to increase the administration of blood products considerably [10] .

Interestingly, the transfusion rate of non-COVID patients who had been admitted during the pandemic was significantly higher than the rates of patients before the pandemic for RBCs (9.7 vs. 6.8 units/patient-day; P = 0.01), for PLTs (13 vs. 5.9; P < 0.001), for FFP (8.75 vs. 4.8; P = 0.01), and for cryo (2.6 vs. 1.7; P = 0.3). A possible explanation for these findings is given the condition caused by the quarantine and social restrictions, there was an overwhelming fear among patients to visit hospitals. This delay in referral may cause the disease to deteriorate and increase the need for blood transfusion. Furthermore, given the prevailing condition in the hospital, the increase in the number of COVID-19 patients, a reduced hospitalization capacity, and also an impaired operating room availability and efficiency physicians adopt more conservative strategies to sustain life and improve patients' outcomes, including blood transfusion.

In summary, during the first and second waves of the COVID-19 outbreak in Iran, the overall transfusion of blood components decreased. However, from an organizational standpoint, we faced additional challenges as we attempted to address both COVID-19 and concurrent transfusion needs of non-COVID wards. This emphasizes the need for more targeted measures and interventions by precisely following recommended clinical guidelines on blood transfusion. 7 .05 a Transfusion rates were defined as the number of transfusion events in a month divided by the number of patient-days in that particular month. b Non-Covid patients for the preceding 12 months before the COVID pandemic. c After calculation of the transfusion rate in each month, the mean ± SD was calculated during the studied time frames. d Transfusion rates were compared by the Mann-Whitney U test. 

COVID-19 coronavirus pandemic

Coronavirus disease 2019 (COVID-19) and decrease in blood donation: experience of Iranian Blood Transfusion Organization (IBTO)

Blood transfusion utilization in hospitalized COVID-19 patients

Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State

Transfusion support in COVID-19 patients: Impact on hospital blood component supply during the outbreak

Blood transfusion activity in a general hospital during the COVID-19 pandemic

Impact of COVID-19 on blood centres in Zhejiang province China

The impact of COVID-19 pandemic on blood supplies and transfusion services in Eastern Mediterranean Region

Blood usage at a large academic center in Maryland in relation to the COVID-19 pandemic in 2020

Blood transfusion strategies and ECMO during the COVID-19 pandemic